Stability Indicating Method Development and Validation for Assay of Omeprazole Sodium for Injection by a Rapid RP-HPLC
Omeprazole,13 a member of proton pump inhibitor, used for the treatment of peptic ulcers, it supresses gastric acid secretion by inhibiting H+/K+ ATPase. A new fundamental, rapid and sensitive HPLC method was developed for the assay of Omeprazole sodium for injection. It was validated according to ICH and FDA guidelines 2. The HPLC analysis was performed on Dionex ultimate 3000 system equipped with C-18 (150cm*4.6mm) 5µ column, with a mixture of ammonium acetate and acetonitrile buffer in the ratio 65:35 v/v as the mobile phase at the wavelength (λ) 305nm. The total run time was 8 minutes. The calibration curve was linear for 50-150% range of the analytical concentration of 40mg/ml, r2 was found to be 0.9998. The precision was calculated and % RSD was 0.1 % and the recovery of omeprazole was within the range of 98-102%. Validation parameters like robustness, solution stability studies, specificity and forced degradation studies were performed and found to be within acceptance limits. As compared to other methods, this method was found to be more accurate, linear, precise and specific, with short run time. All the results were acceptable and confirmed that the method is suitable for its intended use in routine quality control analysis.
2. ICH Harmonised Tripartite Guideline.Validation of analytical procedures:text and methodology, Q2(R1),USA,2005:1-13.
3. ICH Guideline:Validation of analytical procedures: text and methodology, in Proceedings of International Conference on Harmonization,Q2(R1), Geneva, Switzerland, 2005.
4. Harshal, K.T. and Mukesh, C.P. Development and Validation of a precise single HPLC Method for Determination of Omeprazole and its related compound in pharmaceutical formulation. Indian journal of pharmaceutical sciences. 1997; 59(3):124-127.
5. Martindale.The Complete Drug Reference, Pharmaceutical Press, London, UK, 2005; 34:1536-5050.
6. Neil MJO, Ed., The Merk Index- An Encyclopedia of Chemicals, Drugs and Biological, Merck Research Laboratories.2006; 14.
7. L.L. Brunton, J.S. Lazo, and K. L. Parker. Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill Professional. 2005;11: 969.
8. P. S. Bonato and F. O. Paias, J. Braz. Chem. Soc.2004; 15(2):318.
9. S. Vyas, A. Patel, K. D. Ladva, H. S. Joshi, and A. H. Bapodra, J. Pharm. Bioallied. Sci.2011; 3(2):310.
10. Kalakonda Sri Nataraj1, Mohammad Badrud Duza1, Kalyani Pragallapati1, Dussa Kiran Kumar. Development and validation of RP-HPLC method for the estimation of omeprazole in bulk and capsule dosage forms. International current pharmaceutical journal.2012; 1(11):366-369
11. Fabio S. Murakami, Ariane P. Cruz, Rafael N. pereira. Development and Validation of a RP‐HPLC Method to Quantify Omeprazole in Delayed Release Tablets. Journal of liquid chromatography and related technologies. 2007; 30(1):113-121.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).